Skip to main content
. 2018 Feb 22;15:55–63. doi: 10.1016/j.ymgmr.2018.02.003

Fig. 1.

Fig. 1

Study protocol.

If patients were classified as having a severe clinical disease course such as continued frequent myopathic attacks at the 38th week (12 weeks after starting standard treatment), then enhanced-dose bezafibrate was permissible.